SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
More SynBiotic content >Investment summary
SynBiotic has announced it is acquiring 50.1% of the shares of several market-leading hemp companies, which are part of hemp industry pioneer Daniel Kruse’s group of companies. There will be a capital increase in kind to fund these acquisitions and €2m in cash will be contributed to the capital reserves of the companies being acquired. This marks another step in SynBiotic’s buy-and-build strategy, whereby management is using its experience in scaling profitable companies to accelerate SynBiotic’s strategy to be a leading platform company in the cannabinoid industry.
Content on SynBiotic















Sector |
---|
Consumer
Access more Consumer content
|
Share price graph
Price performance
% |
1m |
3m |
12m |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
*% relative to local index |